Table 2:
Serological and genetic features of RA and intervening characteristics between RA onset and study follow-up by parity
| Number of Prior Deliveries (Parity) | ||||
|---|---|---|---|---|
| 1+ | 0 | |||
| (n=156) | (n=66) | |||
| Characteristics | n | (%) | n | (%) |
| Rheumatoid Factor at Diagnosis | ||||
| Positive | 81 | (51.9) | 35 | (53.0) |
| Negative | 75 | (48.1) | 31 | (47.0) |
| ACPA at Diagnosis | ||||
| Positive | 98 | (62.8) | 38 | (57.6) |
| Negative | 56 | (35.9) | 25 | (37.9) |
| Missing | 2 | (1.3) | 3 | (4.5) |
| Age at Follow-Up | ||||
| 16–24 | 0 | (0.0) | 1 | (1.5) |
| 25–34 | 3 | (1.9) | 16 | (24.2) |
| 35–44 | 19 | (12.2) | 25 | (37.9) |
| 45–54 | 45 | (28.9) | 16 | (24.2) |
| 55–64 | 49 | (31.4) | 5 | (7.6) |
| 65–74 | 40 | (25.6) | 3 | (4.6) |
|
Duration of Disease-Modifying Anti-Rheumati Drug (DMARD) Use* | ||||
| Never Used | 33 | (21.2) | 14 | (21.2) |
| Used, < 12 months | 19 | (12.2) | 6 | (9.1) |
| Used, 12–23 months | 11 | (7.1) | 8 | (12.1) |
| Used, ≥ 24 months | 79 | (50.6) | 32 | (48.5) |
| Used, unknown duration | 14 | (9.0) | 6 | (9.1) |
| DMARDs Ever Taken for ≥ 6 months | ||||
| None | 39 | (25.0) | 14 | (21.2) |
| Any DMARDs | 114 | (73.1) | 49 | (74.2) |
| Sulfsalazine | 26 | (16.7) | 13 | (19.7) |
| Oral Gold | 9 | (5.8) | 5 | (7.6) |
| Gold Shots | 31 | (19.9) | 10 | (15.2) |
| Methotrexate | 66 | (42.3) | 27 | (40.9) |
| Hydroxychloroquine | 52 | (33.3) | 31 | (47.0) |
| Chloroqulne | 4 | (2.6) | 3 | (4.6) |
| D-Penicillamine | 3 | (1.9) | 0 | (0.0) |
| Cyclophosphamide | 1 | (0.6) | 1 | (1.5) |
| Azathioprine | 5 | (3.2) | 1 | (1.5) |
| Etanercept | 1 | (0.6) | 0 | (0.0) |
| Cyclosporine | 0 | (0.0) | 0 | (0.0) |
| Leflunomide | 0 | (0.0) | 0 | (0.0) |
| Unknown | 3 | (1.9) | 3 | (4.6) |
*
During elapsed time from onset to follow-up